The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson’s disease
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Parkinson's disease psychosis (PDP) is a common and often very disturbing component of Parkinson's disease (PD). PDP consists of hallucinations that are mainly visual and delusions that are often of a paranoid nature. These symptoms can be the most troubling and disruptive of all the manifestations of Parkinson's disease. Current treatment methods include the reduction of anti-Parkinson's medications, a strategy that may worsen the motor problems the medications are prescribed to alleviate, and the introduction of selected antipsychotic medications that carry with them the potential for troubling side effects and serious consequences. Pimavanserin has been developed and studied in clinical trials to specifically address Parkinson's disease psychosis and has been submitted to the U.S. Food and Drug Administration for its approval for this purpose. If this is granted, we believe the evidence of Pimavanserin efficacy, safety and tolerability will position this medication as the first choice for treatment of Parkinson's disease psychosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141 · cited 1×
“The Movement Disorders Society task force on evidence-based medicine concluded that clozapine is efficacious for the treatment of PDP, whereas they found insufficient evidence supporting efficacy of quetiapine treatment of PDP [35].”
BackgroundPredictors of Nursing Home Placement in Parkinson's Disease: A Population‐Based, Prospective Study
Aarsland, D., Larsen, J. P., Tandberg, E., & Laake, K. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb06891.x · Cited by 811
Serotonin control of sleep-wake behavior
Monti, J. M. (2011) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2010.11.003 · Cited by 614
Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group
Ravina, B., Marder, K., Fernandez, H. H., Friedman, J. H., McDonald, W., Murphy, D., Aarsland, D., Babcock, D., Cummings, J., Endicott, J., et al. (2007) · Movement Disorders · doi:10.1002/mds.21382 · Cited by 528 · cited 1×
“diagnosis of PDP were published in 2004 [6].”
BackgroundHuot, P., Johnston, T. H., Darr, T., Hazrati, L., Visanji, N. P., Pires, D., Brotchie, J. M., & Fox, S. H. (2010) · Movement Disorders · doi:10.1002/mds.23083 · Cited by 153 · cited 1×
“The role of serotonin in PDP is further supported by a postmortem, autoradiographic study of 5-HT2A receptors [27].”
BackgroundLenka, A., Jhunjhunwala, K. R., Saini, J., & Pal, P. K. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.04.005 · Cited by 106
Visual plus nonvisual hallucinations in Parkinson's disease: Development and evolution over 10 years
Goetz, C. G., Stebbins, G. T., & Ouyang, B. (2011) · Movement Disorders · doi:10.1002/mds.23835 · Cited by 91 · cited 1×
“Although the symptoms of PDP may be initially mild and not disturbing, over time they are likely to evolve, with the patient experiencing them with increasing frequency and reduced or lost ability to discern the psychosis symptoms from reality [10].”
Background
Metadata
- Authors
- Hermanowicz, S., & Hermanowicz, N.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2016-06
- Volume
- 16
- Issue
- 6
- Pages
- 625-633
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2282305669
- Cited by
- 174
- References
- 7
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.